Exact Sciences
Exact Sciences Shares Rise on Unexpected Reimbursement Rate From CMS for Next-Gen Cologuard Test
The next-generation version of the Cologuard test received FDA approval last month and is expected to launch next year.
In an indirect comparison study by researchers in Germany, a fecal immunochemical test showed similar sensitivity and specificity as Exact Sciences' Cologuard Plus test.
The researchers used publicly available data from companies such as Guardant Health, Exact Sciences, and Geneoscopy to determine possible effects of blood-based tests.
Caris Life Sciences, ECOG-ACRIN to Analyze Breast Tumor Samples From Landmark TAILORx Study
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
Exact Sciences Nabs FDA Approval for Cologuard Plus Assay
The stool-based test is the next-generation version of Exact's existing Cologuard test for colorectal cancer screening.